Bvlgari supports Oxford Astra Zeneca vaccine — LUXURYMAG

On Monday January 4, 2021 the first person he was vaccinated was 82letý Brian Pinkera vaccine developed by the company AstraZeneca in collaboration with Oxford University. Starting this week, more than half a million doses of this vaccine will be available.

The Bvlgari brand has closely supported the development of the “Oxford vaccine” since June 2020, when it established a philanthropic collaboration with the university’s Jenner Institute.

Sarah Gilbert, Professor of Vaccinology at the University of Oxford she shared: “Today is a significant day for the entire team that participated in the development of the vaccine. We have completed a year of extremely demanding work in non-standard conditions. Now that the results of clinical trials have secured us the first authorization and use of the vaccine, we face additional challenges and will strive to obtain additional data that will multiply the number of regulatory approvals. Our goal is to enable the vaccine to save lives around the world.”

Bvlgari donated a cytometer

Earlier, Jean Christophe Babin and Professor Sarah Gilbert, as representatives of the Bvlgari brand and the University of Oxford, announced a significant donation as part of Bvlgari’s commitment to building a pandemic-free future. The contribution from Bvlgari enabled Oxford to purchase a state-of-the-art flow cytometer, an instrument key to the development of the vaccine candidate.

Jean-Christophe Babin, President and CEO of Bvlgari, to this he said: “I congratulate the University of Oxford on this unique feat. We are incredibly proud to have been able to participate with a modest contribution in the journey full of challenges, at the end of which stands a new vaccine. We look forward to continuing our collaboration with Oxford in the coming years to eradicate more viruses.”

Scholarship program

Thanks to the donation from Bvlgari, a scholarship program for vaccine research could also be established at Oxford University (Bvlgari Scholarship for vaccine research). The first two fellows, Rebecca Makinson and Cameron Bissett, began their PhD studies in October 2020 with research targeting the immune response to the Oxford vaccine candidate.

Professor Louise Richardson, Vice-Chancellor, University of Oxford to this he adds: “This is a great day for British science and universities around the world. And above all, it is a special day for many people whose lives will be saved by this vaccine. We are greatly indebted to those who designed, developed, manufactured and evaluated the ChAdOx1 vaccine.”

Photo source: Bvlgari, Pixabay.com